 Connection
Tyler Buckner to Antibodies, Bispecific
This is a "connection" page, showing publications Tyler Buckner has written about Antibodies, Bispecific.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.504 |
|
|
|
-
Buckner TW, Carpenter SL, Daoud N, Kempton CL, Lee L, Malec L, McLean TW, Morton P, O'Neill C, Staber JM, Wang M, Croteau SE, Recht M. Safety and Effectiveness of Emicizumab in People With Haemophilia A Enrolled in the ATHN 7 Haemophilia Natural History Study. Haemophilia. 2026 Jan-Feb; 32(1):63-70.
Score: 0.887
-
Hermans C, Skinner MW, Gentile B, Lim E, Minhas M, Moreno K, Tzeng E, Buckner TW. Pain-Related Quality of Life Outcomes in People With Haemophilia A Receiving Emicizumab: A Post Hoc Analysis of the HAVEN 1, 3 and 4 and STASEY Studies. Haemophilia. 2025 Jan; 31(1):87-98.
Score: 0.833
-
Buckner TW, Watson C, Recht M. Emicizumab in Hemophilia A. N Engl J Med. 2020 02 20; 382(8):785-786.
Score: 0.596
-
Astermark J, Buckner TW, Frenzel L, Hatswell AJ, You X, Liu H, Goodman E, Santos S, Hawes C, Hinds D, Klamroth R. Matching-adjusted indirect comparison of bleeding outcomes in severe haemophilia A: Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis. Haemophilia. 2023 Jul; 29(4):1087-1094.
Score: 0.188
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|